Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 28, 2017
Pharmacy Choice - News - Generic Drugs - July 28, 2017

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 84     Next >>     Go To Page:

7/28/17 - Baxter Completes Acquisition of Claris Injectables, Expanding Generic Injectable Medicines Portfolio
DEERFIELD, Ill.,- Baxter International Inc., a global medical products company, today announced the completion of the acquisition of Claris Injectables Limited, a global generic injectables pharmaceutical company. "The combination of Baxter and Claris Injectables will allow us to increase access to lower-cost generic injectables and strengthen our
7/28/17 - Baxter Reports Second-Quarter 2017 Results and Provides Updated Financial Outlook for 2017 and 2020
*Second-Quarter GAAP Earnings Per Share of $0.48; Adjusted EPS of $0.63 Increased 37 Percent. *Raises Full-Year 2017 GAAP EPS to $1.85 to $1.95; Adjusted EPS to $2.34 to $2.40. DEERFIELD, Ill.,- Baxter International Inc. today reported results for the second quarter of 2017 and increased its financial outlook for full-year 2017 and 2020..
7/28/17 - Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA [Sudan Tribune]
The goal of the study is to demonstrate that BI 695501 is interchangeable with the U.S.- marketed formulation of Humira* 40 mg/0. 8 mL. This is the first study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate. BI 695501 has been accepted for regulatory review by the European Medicines Agency and th
7/28/17 - Claris Lifesciences sells injectables unit to Baxter [India Infoline News Service]
Claris Lifesciences has completed the planned sale of its generic injectables business to pharmaceutical major Baxter International Inc for USD 625 million. Claris Lifesciences has completed the planned sale of its generic injectables business to pharmaceutical major Baxter International Inc for USD 625 million. Claris Lifesciences will now...
7/28/17 - Concordia International Announces Release Date for Second Quarter 2017 Results
-Concordia International Corp., an international specialty pharmaceutical company focused on generic and legacy pharmaceutical products, today announced it intends to release its second quarter 2017 financial results before market open on Friday, August 11, 2017. The Company will subsequently hold a conference call that same day, Friday, August 11,
7/28/17 - Data from Office of Generic Drugs Advance Knowledge in Coumarins and Indandiones (Integrating In Vitro, Modeling, and In Vivo Approaches to...
Financial support for this research came from U.S. Food and Drug Administration. The news reporters obtained a quote from the research from the Office of Generic Drugs, "Sensitivity analyses indicated that warfarin pharmacokinetics was not sensitive to solubility, particle size, density, or dissolution rate in pH 4.5, but was affected by dissolutio
7/28/17 - Elite Announces Co-Development of Four Additional Products with SunGen Pharma
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company developing abuse-deterrent opioids and niche generic products, today announced Elite and SunGen Pharma, LLC will co-develop four additional generic products bringing the total number of products developed under the amended agreement to eight.. Three products will be owned jointly by
7/28/17 - Findings on Rheumatoid Arthritis Reported by Investigators at Regional Health Service ("Total evidence" network meta-analysis as a tool for improving...
According to news reporting from Florence, Italy, by NewsRx journalists, research stated, "Since biosimilars generally have undergone less clinical research than originators, their place in therapy can be strengthened by increasing the amount of clinical evidence supporting their approval." For more information on this research see: " Total evidenc
7/28/17 - Pfenex CEO Explores the Future of Biosimilars in North America
SMi Group has announced that Mr Patrick Lucy, CEO of Pfenex, has joined the speaker line-up for the 4th annual Biosimilars North America conference which takes place on November 15& 16 in New Jersey. Patrick will present a special keynote address giving an overview of the biosimilars market, including the key milsestones and hurdles the industry
7/28/17 - Rep. Goodlatte Issues Statement at Hearing on 'Antitrust Concerns and the FDA Approval Process'
Bob Goodlatte, R- Va., chairman of the House Judiciary Committee, issued the following statement:. The antitrust laws established in this country serve a valuable role in promoting competition, and the Judiciary Committee routinely exercises its oversight authority to ensure that these laws are applied in a manner that is transparent, fair, predict
7/28/17 - Researchers' Work from University of Michigan Focuses on Adrenal Cortical Steroids (Mechanisms of in vivo release of triamcinolone acetonide from...
According to news reporting originating from Ann Arbor, Michigan, by NewsRx correspondents, research stated, "Little is known about the underlying effects controlling in vitro-in vivo correlations for biodegradable controlled release microspheres. Financial supporters for this research include Office of Research and Standards, Office of Generic Dru
7/28/17 - Sun Pharma increases stake in Zenotech to 57.56% [India Infoline News Service]
Sun Pharmaceutical Industries has announced on Thursday that the company has increased its stake in Zenotech Laboratories from 46.85% to 57.56%. Sun Pharmaceutical Industries has announced on Thursday that the company has increased its stake in Zenotech Laboratories from 46.85% to 57.56%. Zenotech is a pharmaceutical company engaged in developing a
7/28/17 - Teligent, Inc. to Hold Conference Call for Second Quarter 2017 Results
Teligent, Inc., a New Jersey- based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Tuesday, August 8, 2017 to discuss the 2nd quarter 2017 financial results and business update.. The Company invites you to listen to the call by dialing 1-866-393-8366. International participants should c
7/28/17 - Teva Announces Launch of Generic Epiduo in the United States
Teva Pharmaceutical Industries Ltd., today announced the launch of generic Epiduo 1 gel, 0.1%/ 2.5% in the U.S.. With close to 600 generic medicines available, Teva has the largest portfolio of FDA- approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the U
7/28/17 - UNITED THERAPEUTICS CORP FILES (8-K) Disclosing Regulation FD Disclosure
As disclosed previously in the Quarterly Report on Form 10- Q filed by United Therapeutics Corporation on July 27, 2017, the Company is engaged in litigation with Watson Laboratories, Inc. based on Watson's Abbreviated New Drug Application seeking approval by the U.S. Food and Drug Administration to market a generic version of Tyvaso Inhalation
7/28/17 - United Therapeutics Corporation (NASDAQ:UTHR) Files An 8-K Regulation FD Disclosure
United Therapeutics Corporation (NASDAQ:UTHR) Files An 8-K Regulation FD DisclosureItem 7.01. Regulation FD Disclosure As disclosed previously in the Quarterly Report on Form10-Q (the 10-Q) filed by United Therapeutics Corporation (the Company) on July27, 2017, the Company is engaged in litigation with Watson Laboratories,Inc. (Watso
7/27/17 - Acella Pharmaceuticals, LLC, announces approval of generic to Vituz Oral Solution
Acella Pharmaceuticals, LLC, a leading U.S. developer of specialty pharmaceuticals across several therapeutic categories, recently announced the Food and Drug Administration's approval of the Company's abbreviated new drug application for a Hydrocodone Bitartrate and Chlorpheniramine Maleate Oral Solution 5 mg/4 mg per 5 mL as a bioequivalent...
7/27/17 - Alkermes plc Reports Second Quarter 2017 Financial Results
Alkermes plc today reported financial results for the second quarter of 2017.. Following a pre-NDA meeting with FDA for ALKS 5461 earlier this week, we are on track to begin the rolling submission of the ALKS 5461 New Drug Application next month and expect to complete the submission by year-end 2017. This compared to $195.2 million for the same per
7/27/17 - ALKERMES PLC. - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
Executive Summary Net loss for the three months ended June 30, 2017 was $43.0 million, or $0.28 per ordinary share- basic and diluted, as compared to a net loss of $47.2 million, or $0.31 per ordinary share- basic and diluted for the three months ended June 30, 2016. Net loss for the six months ended June 30, 2017 was $111.9 million, or $0.73 per o
7/27/17 - Baxter Completes Acquisition of Claris Injectables, Expanding Generic Injectable Medicines Portfolio
Baxter International Inc., a global medical products company, today announced the completion of the acquisition of Claris Injectables Limited, a global generic injectables pharmaceutical company. Almeida, chairman and chief executive officer, Baxter. The combination of Baxter and Claris Injectables will allow us to increase access to lower-cost
7/27/17 - Baxter Reports Second-Quarter 2017 Results, Provides Updated Financial Outlook for 2017, 2020
Operationally, Baxter's sales rose 3 percent, adjusting for the impact of foreign exchange, generic competition for U.S. cyclophosphamide and the previously communicated select strategic product exits the company is undertaking. Sales within the U.S. were $1.1 billion, advancing 4 percent. Baxter's operational sales increased 5 percent in the U.S.
7/27/17 - Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and U.S.-formulated Humira
The goal of the study is to demonstrate that BI 695501 is interchangeable with the U.S.- marketed formulation of Humira * 40 mg/0. 8 ml. This is the first study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate. The study will compare the pharmacokinetics and clinical outcomes between patients rec
7/27/17 - Credence Research: New Research - Global Biosimilar Market Analysis, Share, Regional Outlook 2017 - Acute Market Reports
The report titled "Global Biosimilar Market: Trends& Opportunities" analyzes the global biologics market, with exhaustive discussion on demand of Biosimilars with increase in patent expiry of innovator drugs. The key market challenges recognized by the analysts and the major trends biosimilar market are presented in the report. Further, key manufac
7/27/17 - FDA Oncologic Drugs Advisory Committee Unanimously Recommends Approval of Mylan and Biocon's Proposed Biosimilar Trastuzumab
By a News Reporter-Staff News Editor at Women's Health Weekly Mylan N.V. and Biocon Ltd. announced that the U.S. Food and Drug Administration Oncologic Drugs Advisory Committee recommended approval of the companies' proposed biosimilar trastuzumab. We look forward to working with FDA to further increase access to this important treatment option f
7/27/17 - Generic Drugs Tablets And Capsules. [TendersInfo (India)]
Contract notice: Generic Drugs Tablets and Capsules. Value excluding VAT: 27 180 052.00 GBP. Time limit for receipt of tenders or requests to participate: Date: 07/09/2017 Local time: 10:00 Major organization: VELINDRE NHS TRUST, NHS WALES SHARED SERVICES PARTNERSHIP PROCUREMENT SERVICES Address: Procurement Service 4 Th Floor Compaines House Crown
Articles(s): 1 - 25 of 84     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415